Published in 2015 - Ann Oncol (2015) 26 (8): 1573-1588. doi: 10.1093/annonc/mdv187
Authors: W. E. E. Eberhardt, D. De Ruysscher, W. Weder, C. Le Péchoux, P. De Leyn, H. Hoffmann, V. Westeel, R. Stahel, E. Felip, S. Peters
This report from the 2nd ESMO Consensus Conference on Lung Cancer complements existing guidelines and provides recommendations by international experts on guidance substaging stage III NSCLC for decision making, optimal diagnostic work-up, most relevant comorbidities, optimal multimodality combinations for the different substages, optimal chemotherapy, radiotherapy and surgery regimens, patient characteristics to take into account in treatment decisions and the place for targeted agents in stage III NSCLC.